Literature DB >> 32869661

Micropapillary pattern of stage IIIA-N2 lung adenocarcinoma is a prognostic factor after adjuvant chemoradiotherapy.

Jian Zeng1,2,3, Xiaoying Cui2,3,4,5, Lei Cheng2,3,4, Ying Chen1,2,3,4, Xianghui Du2,3,4, Liming Sheng2,3,4.   

Abstract

Aim: This study aims to investigate the significance of a micropapillary pattern in stage IIIA-N2 lung adenocarcinoma after adjuvant chemoradiotherapy. Patients & methods: A total of 257 patients with stage IIIA-N2 lung adenocarcinoma were enrolled in this study. Patients were classified into three groups based on the proportion of micropapillary components: micropapillary negative, micropapillary minor component and micropapillary predominant component.
Results: The micropapillary predominant group had the shortest median disease-free survival and overall survival times compared with the micropapillary minor component and micropapillary negative groups (median overall survival time: 54 months vs 64 months vs not reached; p = 0.004). Furthermore, the micropapillary pattern was an independent prognostic factor for disease-free survival and overall survival (p < 0.05).
Conclusion: The micropapillary pattern of IIIA-N2 lung adenocarcinoma is related to worse prognosis.

Entities:  

Keywords:  adjuvant chemoradiotherapy; micropapillary pattern; non-small-cell lung cancer; prognosis

Year:  2020        PMID: 32869661     DOI: 10.2217/fon-2020-0597

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.

Authors:  Chunguang Wang; Shu Chen; Qianru He; Tingting Sun; Peiran Xu
Journal:  Invest New Drugs       Date:  2022-06-06       Impact factor: 3.651

2.  Enhanced CT-Based Radiomics to Predict Micropapillary Pattern Within Lung Invasive Adenocarcinoma.

Authors:  Yunyu Xu; Wenbin Ji; Liqiao Hou; Shuangxiang Lin; Yangyang Shi; Chao Zhou; Yinnan Meng; Wei Wang; Xiaofeng Chen; Meihao Wang; Haihua Yang
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.